Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Accrued restructuring liability by Year
Accrued restructuring liability ($M) ($M)
Gilead Sciences Accrued restructuring liability: $61M in FY2025, down 34.4% from a year earlier.
Latest, FY2025
61
Period ended Dec 31, 2025
Change on a year earlier
-34.4%
93 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Restructuring Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued restructuring liability ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61 | -34.4% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 93 | – | Form 10-K (filed 2025-02-28) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Accrued restructuring liability ($M), annual FY2024–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/restruct-reserve
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.